# A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain

Source: https://onco.cc/trials/nct06764186/  
OnCo record `nct06764186` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Fulvestrant and Capivasertib in advanced solid tumours, run by AstraZeneca, active and no longer recruiting.

## Summary

A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain is a phase 3 interventional study registered as NCT06764186 by AstraZeneca, with 101 participants enrolled, started 2025-01-07 and due to reach its primary completion in 2027-12-31. Interventions recorded: Fulvestrant and Capivasertib.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06764186
- Phase: 3
- Setting: A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With HR+ / HER2- Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain
- Sponsor: AstraZeneca
- Enrolled: 101

## Sources

- ClinicalTrials.gov NCT06764186: https://clinicaltrials.gov/study/NCT06764186

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Capivasertib](https://onco.cc/drugs/capivasertib/), [Fulvestrant](https://onco.cc/drugs/fulvestrant/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct06764186.json